Neurocrine Biosciences (NBIX) Income from Continuing Operations (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Income from Continuing Operations of 144400000.0 for Q2 2026, up 34.33% year-over-year from 107500000.0 in Q2 2025, and down 27.03% on a QoQ basis from 197900000.0 in Q1 2026.
Neurocrine Biosciences (NBIX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Income from Continuing Operations for 17 years, with the latest figure at 144400000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 144400000.0, up 34.33% year-over-year; the trailing twelve-month figure through Jun 2026 was 705500000.0 (up 102.56% YoY), and the FY2025 annual result was 478600000.0, up 40.23% from the prior year.
- Income from Continuing Operations fell to 144400000.0 in Q2 2026, from 197900000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 209500000.0 in Q3 2025 and troughed at 76600000.0 in Q1 2023.
- A 5-year average of 87022222.22 and a median of 92250000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2023, when Income from Continuing Operations slumped 651.08%; it then soared 2405.06% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 89000000.0 in 2022, then jumped by 65.96% to 147700000.0 in 2023, then plunged by 30.2% to 103100000.0 in 2024, then surged by 49.08% to 153700000.0 in 2025, then decreased by 6.05% to 144400000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 144400000.0 in Q2 2026, 197900000.0 in Q1 2026, and 153700000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144.40 Mn |
| Mar 31, 2026 | 197.90 Mn |
| Dec 31, 2025 | 153.70 Mn |
| Sep 30, 2025 | 209.50 Mn |
| Jun 30, 2025 | 107.50 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Dec 31, 2024 | 103.10 Mn |
| Sep 30, 2024 | 129.80 Mn |
| Jun 30, 2024 | 65.00 Mn |
| Mar 31, 2024 | 43.40 Mn |
| Dec 31, 2023 | 147.70 Mn |
| Sep 30, 2023 | 83.10 Mn |
| Jun 30, 2023 | 95.50 Mn |
| Mar 31, 2023 | -76.60 Mn |
| Dec 31, 2022 | 89.00 Mn |
| Sep 30, 2022 | 68.50 Mn |
| Jun 30, 2022 | -16.90 Mn |
| Mar 31, 2022 | 13.90 Mn |
| Dec 31, 2021 | -7.30 Mn |
| Sep 30, 2021 | 22.50 Mn |